Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) was upgraded by stock analysts at Raymond James to a "moderate buy" rating in a note issued to investors on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech's Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.
Several other brokerages also recently issued reports on ONCY. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday. Leede Financial downgraded shares of Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a report on Wednesday.
Check Out Our Latest Report on ONCY
Oncolytics Biotech Price Performance
Shares of NASDAQ ONCY traded down $0.03 on Thursday, hitting $0.98. The company's stock had a trading volume of 245,358 shares, compared to its average volume of 328,224. Oncolytics Biotech has a 12-month low of $0.84 and a 12-month high of $1.75. The company has a market capitalization of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. The stock has a 50 day moving average of $1.09 and a 200-day moving average of $1.06.
Hedge Funds Weigh In On Oncolytics Biotech
A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,889 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.82% of the company's stock.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
